RESUMEN
@#Objective To investigate the changes and clinical significance of serum caspase-cleaved cytokeratin-18 (CCCK-18) and complement 1q tumor necrosis factor-related protein 3 (CTRP3) levels in patients with acute ischemic stroke (AIS).Methods A total of 163 AIS patients were selected as the AIS group.According to the National Institutes of Health Stroke Scale (NIHSS),the patients were divided into the mild defect group (49 cases),moderate defect group (76 cases),severe defect group (38 cases),after 3 months of treatment,patients were divided into poor prognosis group (66 cases) and good prognosis group (97 cases) according to the modified Rankin scale (mRS),in addition,72 healthy individuals who had physical examination during the same period were selected as the control group.Enzyme-linked immunosorbent assay was used to determine serum CCCK-18 and CTRP3 levels.Results The serum CCCK-18 level in the AIS group was significantly higher than that in the control group,and the CTRP3 level was significantly lower than that in the control group (P<0.05).The serum CCCK-18 level in the mild,moderate,and severe defect groups gradually increased,and the CTRP3 level gradually decreased (P<0.05).The serum CCCK-18 level was positively correlated with NIHSS score,and CTRP3 level was negatively correlated with NIHSS score (P<0.05).Multivariate logistic regression analysis showed that large area infarction,high NIHSS score,high CCCK-18 level were an independent risk factor for poor prognosis in AIS patients,and high CTRP3 level was an independent protective factor (P<0.05).The ROC curve showed that the AUC of CCCK-18 combined CTRP3 predicting poor prognosis of AIS patients was significantly greater than that of CCCK-18,CTRP3 alone predicted(P<0.05),the sensitivity and specificity were 86.36% and 81.44%.Conclusion The serum CCCK-18 level in AIS patients is up-regulated,and the CTRP3 level is down-regulated,which is related to the severity of the disease and poor prognosis.Combined detection of the two can improve the predictive value of poor prognosis.
RESUMEN
Objective To explore the relationship between serum complement 1q (C1q) and C1q/tumor necrosis factor-related protein 1 (CTRP1) levels in patients with coronary atherosclerotic heart disease (CHD) and their clinical value.Methods Case-control study.115 patients with CHD who were hospitalized in the Department of Cardiology of Ningxia Medical University General Hospital from January 2018 to November 2018 were selected as the case group, including 72 males and 43 females, aged 35-82 years, average (59.96 ± 9.49) years old. There were three subgroups: stable angina group (SAP, n=12), unstable angina group (UA,n=69), and acute myocardial infarction group (AMI, n=34). The control group was selected from 43 healthy subjects in the same period, including 21 males and 22 females, aged 23-71 years, with an average of (45.00 ± 10.66) years old. Serum C1q and CTRP1 levels were tested by immunoturbidimetry and ELISA, and other biochemical indicators such as triglyceride (TG) and total cholesterol (CHOL) were detected.Multiple linear regression was used to analyze the influence of various factors on C1q level. ROC curve and area under the curve (AUC) to explore the diagnostic value of C1q and CTRP1. Results The C1q level in the CHD group (184.06±31.05) mg/L was higher than that in the control group (122.22±28.18) mg/L (t=-11.405, P<0.001). The AMI group (192.80 ± 34.08) mg/L was significantly higher than the SAP group (169.17 ± 27.13) mg/L (t=-2.328, P=0.021). The CTRP1 level in the CHD group [241.85(79.38)] ng/ml was lower than that in healthy control group [292.7(67.64)] ng/ml (Z=-3.64, P<0.001). Group B with higher Gensini score (t=3.672, P<0.001) and group C (t=2.529, P=0.013) had higher C1q levels than group A.After adjusting for the effects of age, sex and other indicators, C1q levels were correlated with HDL-C (β=-0.582, P<0.001),CHOL (β=0.384,P<0.001) and systolic blood pressure (β=0.142,P=0.038). The ROC curve shows that when the CHD is diagnosed,the sensitivity of C1q level>150.82 mg/L is 87%,the specificity is 88.4%, and the AUC is 0.942. The corresponding sensitivity and specificity of CTRP1<281.80 ng/ml are 76.5%and 60.5% respectively, and the AUC is 0.688. The AUC obtained by combined predictors was 0.944, and the sensitivity and specificity were 89.6% and 86.0% respectively. When AMI is diagnosed, C1q level >178.3 mg/L, corresponding sensitivity and specificity are 70.6% and 66.1%, the AUC is 0.726, CTRP1 has no diagnostic value. Conclusions Serum C1q levels in patients with CHD are elevated,and AMI patients are higher than SAP patients;C1q may be a potential marker reflecting the severity of coronary artery disease;there is no significant correlation between serum C1q and CTRP1 in CHD patients.
RESUMEN
Objective@#To explore the relationship between serum complement 1q (C1q) and C1q/tumor necrosis factor-related protein 1 (CTRP1) levels in patients with coronary atherosclerotic heart disease (CHD) and their clinical value.@*Methods@#Case-control study.115 patients with CHD who were hospitalized in the Department of Cardiology of Ningxia Medical University General Hospital from January 2018 to November 2018 were selected as the case group, including 72 males and 43 females, aged 35-82 years, average (59.96±9.49) years old. There were three subgroups: stable angina group (SAP, n=12), unstable angina group (UA, n=69), and acute myocardial infarction group (AMI, n=34). The control group was selected from 43 healthy subjects in the same period, including 21 males and 22 females, aged 23-71 years, with an average of (45.00±10.66) years old. Serum C1q and CTRP1 levels were tested by immunoturbidimetry and ELISA, and other biochemical indicators such as triglyceride (TG) and total cholesterol (CHOL) were detected.Multiple linear regression was used to analyze the influence of various factors on C1q level. ROC curve and area under the curve (AUC) to explore the diagnostic value of C1q and CTRP1.@*Results@#The C1q level in the CHD group (184.06±31.05) mg/L was higher than that in the control group (122.22±28.18) mg/L (t=-11.405, P<0.001). The AMI group (192.80±34.08) mg/L was significantly higher than the SAP group (169.17±27.13) mg/L (t=-2.328, P=0.021).The CTRP1 level in the CHD group [241.85(79.38)] ng/ml was lower than that in healthy control group [292.7(67.64)] ng/ml (Z=-3.64, P<0.001). Group B with higher Gensini score (t=3.672, P<0.001) and group C (t=2.529, P=0.013) had higher C1q levels than group A.After adjusting for the effects of age, sex and other indicators, C1q levels were correlated with HDL-C (β=-0.582, P<0.001),CHOL (β=0.384,P<0.001) and systolic blood pressure (β=0.142,P=0.038). The ROC curve shows that when the CHD is diagnosed, the sensitivity of C1q level >150.82 mg/L is 87%,the specificity is 88.4%, and the AUC is 0.942. The corresponding sensitivity and specificity of CTRP1 <281.80 ng/ml are 76.5% and 60.5% respectively, and the AUC is 0.688. The AUC obtained by combined predictors was 0.944, and the sensitivity and specificity were 89.6% and 86.0% respectively. When AMI is diagnosed, C1q level >178.3 mg/L, corresponding sensitivity and specificity are 70.6% and 66.1%, the AUC is 0.726, CTRP1 has no diagnostic value.@*Conclusions@#Serum C1q levels in patients with CHD are elevated, and AMI patients are higher than SAP patients; C1q may be a potential marker reflecting the severity of coronary artery disease; there is no significant correlation between serum C1q and CTRP1 in CHD patients.
RESUMEN
Objective:To study expression of complement C1q tumor necrosis factor related protein 3 (CTRP‐3 ) in obese patients and its significance .Methods :A total of 402 obese patients were enrolled as obesity group and 405 normal people undergoing physical examination were regarded as normal control group . The correlation among CTRP‐3 level and related indexes were analyzed ,and multi-factor regression analysis was used to study independent risk factors for obesity .Results:Compared with normal control group ,there were significant rise in body mass index (BMI) ,homeostasis model -insulin resistance index (HOMA-IR) ,levels of systolic blood pressure (SBP) ,diastolic blood pressure (DBP) ,total cholesterol (TC) ,low density lipoprotein cholesterol (LDL‐C) ,triglyceride (TG) ,fasting blood glucose (FBG) ,insulin ,glycosylated hemoglobin (HbA1c) and high sensitive C reactive protein (hsCRP) ,and significant reductions in levels of high density lipoprotein cholesterol (HDL‐C) ,adiponectin (APN) ,leptin and CTRP‐3 in obesity group , P<0.05 or <0.01 . Spearman correlation analysis indicated that after age and gender correction ,CTRP‐3 level was significant inversely correlated with BMI (r= -0.221) ,SBP (r= -0.031) ,DBP (r= -0.043) ,TC (r= -0.147) , LDL‐C (r= -0.051) ,TG (r= -0.743) ,FBG (r= -0.238) ,insulin (r= -0.053) ,HOMA -IR (r= -0.281) , HbA1c (r= -0.741) and hsCRP levels (r= -0.216) ,P<0.05 or <0.01 ,and significant positively correlated with lev‐els of HDL‐C (r=0.351) ,APN (r= 0.852) and leptin (r=0.641) ,P<0.05 all .Multi-factor regression analysis indi‐cated that after correcting other influencing factors ,compared with high tertile CTRP‐3 group ,there were significant rise in OR value in middle tertile CTRP‐3 group (OR=6.47 ,95% CI 3.58 -12.18) and low tertile CTRP‐3 group (OR=12.39 ,95% CI 3.58-29.15) , P<0.01 all .Conclusion:CTRP‐3 level is significantly correlated with obesity -related fac‐tors ,and it′s an independent risk factor for obesity .
RESUMEN
Objective To analyze the correlation between serum anti-C1q antibody (anti-C1q Ab)and renal pathological characteristic,disease activity as well as some laboratory tests in patients with lupus nephritis (LN).Methods Serum anti-C1q antibodies were detected by enzyme-linked immunosorbant assay ELISA) in 120 patients with systemic lupus nephritis (SLE),which included 60 LN patients and 60 non-LN patients.Renal biopsy was conduted in all LN patients.The relationships between serum anti-C1q Ab level and renal pathohistology,lupus nephritis activity,as well as some laboratory parameters were analyzed.Results The mean level of serum anti-C1q Ab in LN patients was (89+26) U/ml,significantly higher than that of nonLN patients (57±23) U/ml (P<0.01).Twelve cases of renal biopsies were classified as WHO Class Ⅱ,fourteen cases Class Ⅲ,eighteen cases Class Ⅳ,and sixteen cases Class Ⅴ.Significant difference of serum anti-C1q Ab level between each class was found by ANOVA test,and serum anti-C1q Ab level of Class Ⅳ was the highest (P<0.01).Renal biopsies showed a positive correlation between serum anti-C1q Ab level and activity index of renal pathohistology (P<0.01).Renal deposition of C1q was related with the level of serum anti-C1q Ab.Serum anti-C1q Ab level was positively correlated with proteinuria (P<0.01),and negatively correlated with levels of C3 and C4 (P<0.01).Mean level of serum anti-C1q antibody in SLE patients with positive antidsDNA was higher than that in the patients with negative anti-dsDNA (P<0.01).Conclusion Serum antiC1q Ab level is significantly associated with lupus nephritis activity and renal pathohistology.It is a useful marker to predict renal lesion and disease activity in lupus nephritis.
RESUMEN
Objective To explore the relationship between clinical and pathological changes of complement 1q(C1q) nephropathy. Methods Clinical manifestation, pathologic features including glomerulus change, renal tubule - interstitial change and im-munopathology were compared between 10 cases of C1q nephropathy in children, who were diagnosed by renal biopsy. Results Presentation included idiopathic nephritic syndrome(6 cases), simple hematuria(2 cases), nephritic syndrome(1 case), rapidly progressive glomerulonephritis( 1 case); Renal biopsy revealed focal segmental glomerulosclerosis( FSGS) in 5, minimal-change disease( MCD) and mesangial proliferative glomerulonephritis (MsPGN) respectively in two and crescentic glomerulonephritis in one. In addition, there were renal - tubule interstitial changes with 3 cases of grade I and grade II each other, 2 of grade III , 1 of grade IV . The prominent immunofluorescent features was the presence of bright mesangial deposition of C1q. The average follow - up time was 25.7 months. Six cases presenting nephrotic syndrome were resistant to steroid, but 5 were released after immunosuppressive therapy, the other had progressive renal insufficiency. Conclusions C1q nephropathy falls with the clinical - pathologic spectrum of FSGS generally. It is also presented as steroid - resistant nephritic syndrome. Moreover, the prognosis of C1q nephropathy is related to renal tubulointerstitial pathologic lesions not to C1q deposition.
RESUMEN
Objective To detect the serum level of complement 1q (C1q) and anti-C1q autoantibodies (C1qAb) in systemic lupus erythematosus (SLE) patients to analyze the correlation of serum level of C1q and C1qAb with renal lesion and disease activity in SLE. Methods The serum level of C1q and C1qAb were detected by single radial lmnmnodiffusion and enzyme-linked immunosorbent assay respectively. Results The serum level of C1q in SLE patients was significantly lower than that of the control groups. The serum level of C1qAb in SLE patients was significantly higher than that of the control groups. There was a strong correlation between the serum level of C1q and C1qAb in SLE patients. SLE patients in flare stage showed a significantly higher level of serum C1qAb and a lower level of serum C1q than stable patients. Lupus nephritis(LN) patients showed a significantly higher level of serum C1qAb and a lower level of serum C1q than non-LN patients. Conclusions Low level of serum C1q and the high level of serum C1qAb are correlated with SLE. The serum level of C1q and C1qAb are significantly correlated with renal lesion and disease activity of SLE patients.